Kirstin Cosgrove

Ms. Kirstin Cosgrove


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Medical Research Archives
Verified
Journal Article
Open access
PDF file
MMM. Nathaniel Mead
M. Nathaniel Mead
JRJessica Rose
Jessica Rose
Stephanie SeneffStephanie Seneff
Stephanie Seneff
CRClaire Rogers
Claire Rogers
Nicolas HulscherNicolas Hulscher
Nicolas Hulscher
Peter A McCulloughPeter A McCullough
Peter A McCullough
COVID-19 can have short- and long-term health consequences, including various cardiovascular, respiratory, hematologic, autoimmune, and neurological conditions. Although it is often claimed that COVID-19 mRNA vaccinations reduce COVID-19 severity and post-acute sequelae, these assertions are refuted by evidence of extensive mRNA immunization-related harms that appear to be amplified by SARS-CoV-2 infection, resulting in considerable overlap in reported adverse outcomes. Spike proteins from both sources persist in the human body over the long-term, leading to immune dysfunction, inflammation, autoimmunity, organ dysfunction, and overlapping toxicities. We hypothesize that the mRNA vaccinations create a persistent toxic milieu of spike protein, inflammatory lipid nanoparticles, and DNA impurities, amplifying morbidity and mortality risks commonly ascribed to SARS-CoV-2 infection. Many 2021-2024 morbidity/mortality events in highly vaccinated populations, though often attributed solely to COVID-19 illness (due to close temporal associations with laboratory-confirmed infection), were more likely to result from these interactions or “hybrid harms”. Evidence supporting our hypothesis includes studies of negative efficacy, overlapping pathologies (e.g., myocarditis and thrombosis), redundant mechanisms, and epidemiological surges in excess mortality during the Omicron era (since December 2021) in extensively vaccinated countries. Case report data indicate that spike protein production along with associated “spikeopathies” may persist for at least three years, during which a coronavirus infection could trigger a new disease syndrome that would logically be attributed to the infection based on the timing. In contrast there is a relatively mild course for Omicron infections in the unvaccinated. Ongoing spike production from prior mRNA vaccinations is likely to predispose Omicron-infected individuals to cumulative adverse effects over time. The amplified toxicities and immunopathologic effects may help account for near-synchronous waves of COVID-19 and all-cause mortality in the Omicron era. This novel framework calls for re-examining the unique immunopathological consequences of SARS-CoV-2 breakthrough infection in COVID-19 mRNA-vaccinated individuals and consideration of the implications for future public health strategies.

14 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JTJames A Thorp
James A Thorp
CRClaire Rogers
Claire Rogers
KCKirstin Cosgrove
Kirstin Cosgrove
SHSteven Hatfill
Steven Hatfill
PBPeter Breggin
Peter Breggin
Peter A McCulloughPeter A McCullough
Peter A McCullough
Introduction: COVID-19 mRNA vaccines are known to penetrate the blood-brain barrier and could potentially cause a myriad of unintended adverse effects. The purpose of this study is to explore potential associations between vaccination and neuropsychiatric conditions. Methods: Data were collected from the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The CDC/FDA Vaccine Adverse Event Reporting System (VAERS) was queried from January 1, 1990, to December 27, 2024, for adverse events (AEs) involving neuropsychiatric complications following COVID-19 vaccination. The timeframe included 420 months for all vaccines except COVID-19 vaccines which have been available to the public for only 48 of the 420 months (from January 1, 2021, to December 27, 2024). Proportional reporting ratios (PRRs) were calculated by time comparing AEs after COVID-19 vaccination to those after influenza vaccination and to those after all other vaccines. The CDC/FDA stipulates a safety concern if a PRR is ≥ 2. Results: Comparing COVID-19 vaccination to influenza vaccinations, the CDC/FDA’s safety signals (PRR, 95% confidence interval, p-value, Z-score) were breached for the following combinations: 47 AEs associated with cognitive impairment (PRR: 118, 95% CI: 87.2-160, p < 0.0001, Z-score: 30.9); 28 AEs associated with general psychiatric illness (PRR: 115, 95% CI: 85.1-156, p < 0.0001, Z-score: 30.8); and 11 AEs associated with suicide/homicide (PRR: 80.1, 95% CI: 57.3-112, p < 0.0001, Z-score: 25.7). Likewise, when comparing COVID-19 vaccination to all other vaccines except COVID-19, the safety signals were also breached for the following: 47 AEs associated with cognitive impairment (PRR: 26.8, 95% CI: 19.8-36.1, p < 0.0001, Z-score: 21.5); 28 AEs associated with general psychiatric illness (PRR: 28.6, 95% CI: 21.2-38.6, p < 0.0001, Z-score: 21.9); and 11 AEs associated with suicide/homicide (PRR: 14.0, 95% CI: 10.3-19.0, p < 0.0001, Z-score: 16.8). Conclusions: There are alarming safety signals regarding neuropsychiatric conditions following COVID-19 vaccination, compared to the influenza vaccinations alone and to all other vaccinations combined. These data raise concerns about long-term consequences, including continued cognitive decline, dementia, and neuropsychiatric morbidity and mortality. An immediate global moratorium on COVID-19 vaccination is warranted.

14 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMM. Nathaniel Mead
M. Nathaniel Mead
JRJessica Rose
Jessica Rose
Stephanie SeneffStephanie Seneff
Stephanie Seneff
CRClaire Rogers
Claire Rogers
BCBreanne Craven
Breanne Craven
Peter A McCulloughPeter A McCullough
Peter A McCullough
The coronavirus disease of 2019 (COVID-19) has the potential to cause or promote a number of health problems in both the short and long terms. It is often claimed that the COVID-19 messenger RNA (mRNA) vaccinations can reduce the severity of COVID-19 and its sequelae. We counter this claim with evidence and moreover hypothesize that the mRNA vaccinations are triggering mechanisms that result in an amplification of COVID-19 morbidity along with the “post-acute sequelae of COVID-19” or PASC. Since 2021, the coronavirus infections were often superimposed on a preexisting mRNA vaccine-induced milieu of toxic spike protein, inflammatory lipid nanoparticles, and residual process-related DNA impurities. Spike proteins resulting from both the mRNA vaccination and the natural SARS-CoV-2 infection have been shown to persist for extended periods, raising parallel concerns regarding potential implications for long-term safety with this vaccination. Many, if not most, of the morbidity and mortality events attributed to COVID-19 in extensively-vaccinated populations in 2022-2023 were due to the long-term background persistence of spike protein and other vaccine-associated components resulting from previous COVID-19 mRNA vaccinations. Although close temporal associations with laboratory-confirmed SARS-CoV-2 often engendered the assumption of viral causation, the morbidity and mortality events are plausibly attributed to a combination of mass vaccination and coronavirus infections. The overlapping spike-related toxicities and immunological effects of mRNA vaccinations and coronavirus infections have resulted in pronounced immune dysregulation and inflammatory cascades that likely account for near-synchronous waves of COVID-19 and all-cause mortality. We present research suggesting a potential for coronavirus infection-induced amplification of adverse events (AEs) associated with the COVID-19 mRNA vaccinations, including a diverse range of cardiovascular, hematological, autoimmune, and neurological conditions that frequently overlap with PASC. In this paper, we coin the phrase “Hybrid Harms Hypothesis”, which calls for re-examining the unique immunopathological dynamics of coronavirus infection in COVID-19 mRNA-vaccinated individuals and their implications for public health strategies.

5 November 2025 in International Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
KCKirstin Cosgrove
Kirstin Cosgrove
JTJames A Thorp
James A Thorp
CRClaire Rogers
Claire Rogers
SHSteven Hatfill
Steven Hatfill
Nicolas HulscherNicolas Hulscher
Nicolas Hulscher
Peter A McCulloughPeter A McCullough
Peter A McCullough
Background: Neuroinflammatory conditions involving the central nervous system (CNS) are on the rise and while the etiology is currently unknown the parallel rise in cases to mass COVID-19 vaccination is of particular interest. This study explores the association between the CNS infection rate and vaccination. Methods: This is a retrospective study. Retrospective data were utilized from the U. S. centers for disease control and prevention (CDC) and the U.S. food and drug administration (FDA) vaccine adverse event reporting system (VAERS). Adverse events (AEs) encompassing CNS conditions following all vaccines were queried from January 1, 1990, through November 30, 2024. The timeframe for all vaccines except COVID-19 vaccines was 419 months and the timeframe for COVID-19 vaccines was 47 months (January 1, 2021, to November 30, 2024). Observed AEs are presented as odds ratios (ORs) by time which compare these events occurring after COVID-19 vaccination to those after influenza vaccination and to those after all other vaccines. Results: Comparing COVID-19 vaccination to annual influenza vaccinations and all vaccines combined, the CDC/FDA’s safety signal thresholds were breached for the multiple outcomes. Data are expressed as OR, 95% confidence interval (CI), p value, Z score. All CNS categories reviewed produced a safety signal when comparing events after COVID-19 vaccination to influenza vaccination (referent). Thirty-nine events were categorized as CNS infection (29.4, 21.6-40.1, <000.1, 21.4); 11 events grouped as herpetic CNS Infection (171, 93.9-312, <000.1, 16.8); and 4 categorized as CNS abscess (107, 40.9-280, <000.1, 9.53). Similarly, CNS Infections, herpetic CNS infection, and CNS abscess categories also produced a safety signal when comparing events after COVID-19 vaccination to all vaccines combined (referent) (except COVID-19): 39 events categorized as CNS Infections (4.11, 3.03-5.57, <000.1, 9.09); 11 events grouped as herpetic CNS Infection (22.3, 15.4-32.4, <000.1, 16.4) and; 4 events noted as CNS abscess (17.8, 10.5-30.4, <000.1, 10.6). When comparing COVID-19 vaccination to influenza vaccination as well as all vaccines combined, 7 of 9 events in the uncommon neurological disease grouping exceeded safety thresholds for both comparisons. Conclusions: All safety signals reported are concerning and support an immediate global ban on the COVID-19 vaccination program.

6 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSteve Kirsch
Steve Kirsch
PMPaul Marik
Paul Marik
CRClaire Rogers
Claire Rogers
KCKirstin Cosgrove
Kirstin Cosgrove
MMM. Nathaniel Mead
M. Nathaniel Mead
We revisit a 2023 JAMA-published analysis of data from patients admitted for either COVID-19 or influenza to U.S. Veterans Administration (VA) hospitals in the fall/winter of 2022-2023. We note that baseline characteristics between the cohorts were similar, and the difference in vaccination rates was minimal, even after propensity score weighting. Had the vaccines been even minimally effective, significant differences in vaccination percentages would be expected. These findings call into question any efficacy claims associated with either the COVID-19 or influenza vaccines. Furthermore, the lack of efficacy of the influenza vaccines in reducing hospitalization is consistent with an earlier detailed study that found the same lack of efficacy, further validating the current result. This suggests that comparing vaccination rates between those hospitalized for different vaccine-preventable diseases can serve as a practical method for validating the vaccine efficacy claims of different vaccines.

12 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ENErik Nilssen
Erik Nilssen
JTJames A Thorp
James A Thorp
CRClaire Rogers
Claire Rogers
KCKirstin Cosgrove
Kirstin Cosgrove
SHSteven Hatfill
Steven Hatfill
Peter A McCulloughPeter A McCullough
Peter A McCullough
Introduction: COVID-19 mRNA vaccines are associated with the development of a wide range of autoimmune diseases. Rare autoimmune conditions, such as polymyalgia rheumatica (PMR), have received limited attention in medical literature. The purpose of this study is to review PMR, examine reports of PMR in the government database monitoring vaccine safety, and evaluate the potential association between PMR, COVID-19 vaccination, and spike protein antibody levels.Methods: Data were obtained from the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The CDC/FDA Vaccine Adverse Event Reporting System (VAERS) was queried for reports of polymyalgia rheumatica (PMR) from January 1, 1990, through January 30, 2026. This period encompasses 433 months for all vaccines; however, COVID-19 vaccines were available to the public for only 61 of those 433 months (January 1, 2021, through January 30, 2026). Odds ratios over time (ORt) were calculated by comparing the occurrence of PMR following the administration of specific vaccinations to including COVID-19, influenza, and all other vaccines combined. The CDC/FDA defines a safety signal as a disproportionality measure of ≥ 2. Data are presented as odds ratios over time ORt with corresponding 95% confidence intervals, p-values, and Z statistics. Three cases of PMR from the authors’ recent clinical practices were reviewed. A literature review on PMR was conducted using PubMed, MEDLINE, and Google Scholar.Results: Significant safety signals were observed when comparing reports of PMR following COVID-19 vaccination with those following influenza vaccination. This association persisted when PMR following COVID-19 vaccination was compared with PMR following all other vaccines combined. There were 2,227 reported cases of PMR following COVID-19 vaccination during the 61 months after vaccine rollout. In comparison, 233 cases were reported following influenza vaccination, and 526 cases were reported following all other vaccines combined over a 433-month period. The ORt for COVID-19 vaccination compared with influenza vaccination was 69.4, 95% CI 51.4 - 93.6, p < 0.0001, Z statistic 27.7. When comparing PMR following COVID-19 vaccination with PMR following all other vaccines combined including influenza, a significant safety signal persisted: 30.7, 95% CI 23.1 - 40.8, p < 0.0001, 23.6. Three exemplary cases and a review of the literature are also presented. Conclusions: Strong safety signals were detected when comparing polymyalgia rheumatica (PMR) following COVID-19 vaccination with PMR following influenza vaccination and, when compared to all other vaccines combined. The strength of the signal, its statistical robustness, and its consistency with observed clinical cases and biologically plausible immunoinflammatory mechanisms suggest the need for heightened clinical awareness of PMR occurring temporally following COVID-19 vaccination. These findings corroborate other research documenting the occurrence of PMR after COVID-19 vaccination and the pathophysiological pathway for spike protein-induced autoimmunity. Future research should prioritize validation of direct assays for spike protein detection rather than relying solely on surrogate antibody measurements. Additional investigation is also warranted to clarify the role of COVID-19 vaccinations and spike protein in musculoskeletal pathology and to evaluate preventive and therapeutic strategies.